Tapentadol extended release in the management of peripheral diabetic neuropathic pain

Ther Clin Risk Manag. 2015 Jan 14:11:95-105. doi: 10.2147/TCRM.S32193. eCollection 2015.

Abstract

Tapentadol, a μ-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more traditional opioid-based therapies. More recently, tapentadol extended release has been demonstrated to be effective in the management of painful diabetic neuropathy, an often debilitating condition affecting approximately one-third of all patients with diabetes. This review highlights the most up-to-date basic and clinical studies by focusing on the mechanisms of action of tapentadol and its clinical efficacy, especially with regard to painful diabetic neuropathy.

Keywords: analgesia; chronic pain; neuropathic pain; pain management; pharmacology.

Publication types

  • Review